Results 51 to 60 of about 8,252,790 (324)

The processes of reform in Victoria’s alcohol and other drug sector, 2011-2014 [PDF]

open access: yes, 2014
This paper explores issues and concerns related to the 2014 alcohol and other drug sector recommissioning process in Victoria. Overview In mid-2014, the Victorian Alcohol and Drug Association approached the Drug Policy Modelling Program, at the ...
Drug Policy Modelling Program
core  

Physicians’ familiarity and comfort with the FDA drug approval process.

open access: yes, 2016
Physicians’ familiarity and comfort with the FDA drug approval process.
Lisa A. Fulchino (725557)   +8 more
core   +1 more source

Social Functioning Within the First Years After Pediatric Brain Tumor Diagnosis and the Relationship With Family Psychosocial Risk

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Survivors of pediatric brain tumors (PBTs) can experience long‐term social difficulties, impacting quality of life. Beyond medical and environmental factors, family psychosocial risk may play a role in social outcomes by shaping the caregiving environment and may provide intervention options.
Renske H. Houben   +4 more
wiley   +1 more source

Drug approval process efficiency

open access: yes, 2009
This diploma thesis focuses on drug approval efficiency. It is obvious that the drug approval process is lengthy and expensive. The question that arises is whether the length of the drug approval process, as well as associated costs, leads to better ...
Hlaváčová, Markéta
core   +2 more sources

The challenges of access to innovative medicines with limited evidence in the European Union

open access: yesFrontiers in Pharmacology, 2023
The European Medicines Agency (EMA) fosters access to innovative medicines through accelerated procedures and flexibility in the authorization requirements for diseases with unmet medical needs, such as many rare diseases as well as oncological diseases.
Antonio Vallano   +7 more
doaj   +1 more source

Retrospective Analysis of Donor Lymphocyte Infusions in Pediatric Patients With Mixed Chimerism After Hematopoietic Stem Cell Transplantation

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Allogeneic hematopoietic stem cell transplantation (alloHSCT) is an essential therapy for several malignant and nonmalignant diseases, but relapse and graft loss remain the principal threats to its success. Routine monitoring of chimerism and minimal residual disease (MRD) enables early detection of imminent recurrence and guides ...
Carmen Junk   +10 more
wiley   +1 more source

A Significant Anticancer Drug Approval Lag Between Japan and the United States Still Exists for Minor Cancers

open access: yesClinical pharmacology and therapy, 2018
Reports have indicated that approval lag for anticancer drugs between Japan and the United States has decreased. However, if this is also true for drugs used to treat minor cancers remains unknown.
Kenji Yamashita, M. Kaneko, M. Narukawa
semanticscholar   +1 more source

Pediatric Idiopathic Multicentric Castleman Disease Is Often Severe But Responsive to Siltuximab

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Idiopathic multicentric Castleman disease (iMCD) is a potentially fatal immunologic disorder marked by widespread lymphadenopathy and inflammation. Siltuximab, an interleukin‐6 (IL‐6) inhibitor, is the only FDA‐approved treatment for adult patients with iMCD.
Bridget Austin   +17 more
wiley   +1 more source

Venetoclax‐Based Therapy as a Bridge to Hematopoietic Stem Cell Transplantation in Relapsed or Refractory Pediatric Acute Leukemia

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Relapsed and/or refractory (R/R) pediatric acute leukemia carries a dismal prognosis, largely driven by chemoresistance to conventional salvage therapy. The BH3‐mimetic venetoclax, combined with chemotherapy or hypomethylating agents, has demonstrated efficacy in small clinical trials.
Katherine S. Colman   +9 more
wiley   +1 more source

A Comparative Analysis of Drug Testing and Regulations with a Focus on Antibody Drug Conjugate (ADC) Approval

open access: yes, 2015
The goal of this project, sponsored by Hangzhou DAC Biotech, was to conduct a comparative analysis of the drug approval process for three agencies, with a focus on antibody drug conjugates (ADCs).
Michelini, Stephen Dominic   +3 more
core   +3 more sources

Home - About - Disclaimer - Privacy